Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-clear Cell Renal Cell Carcinoma: A Multi-institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Memorial Sloan Kettering Cancer Center (MSKCC) risk models were developed predominantly with clear cell renal cell carcinoma (RCC). Accordingly, whether these two models could be applied to metastatic non-clear cell RCC (mNCCRCC) as well has not been wellknown and was investigated herein. Materials and Methods From the Korean metastatic RCC registry, a total of 156 patients (8.1%) with mNCCRCC among the entire cohort of 1,922 patients were analyzed. Both models were applied to predict first-line progression-free survival (PFS), total PFS, and cancer-specific survival (CSS). Results The median first-line PFS, total PFS, and CSS were 5, 6, and 24 months, respectively. The IMDC risk model reliably discriminated three risk groups to predict survival: the median firstline PFS, total PFS, and CSS for the favorable, intermediate, and poor risk groups were 9, 5, and, 2 months (p=0.001); 14, 7, and 2 months (p < 0.001); and 41, 21, and 8 months (p < 0.001), all respectively. The MSKCC risk model also reliably differentiated three risk groups: 9, 5, and, 2 months (p=0.005); 10, 7, and 3 months (p=0.002); and 50, 21, and 8 months (p < 0.001), also all respectively. The concordance indices were 0.632 with the IMDC model and 0.643 with the MSKCC model for first-line PFS: 0.748 and 0.655 for CSS. Conclusion The current IMDC and MSKCC risk models reliably predict first-line PFS, total PFS, and CSS in mNCCRCC.
Abstract
Purpose The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Memorial Sloan Kettering Cancer Center (MSKCC) risk models were developed predominantly with clear cell renal cell carcinoma (RCC). Accordingly, whether these two models could be applied to metastatic non-clear cell RCC (mNCCRCC) as well has not been wellknown and was investigated herein. Materials and Methods From the Korean metastatic RCC registry, a total of 156 patients (8.1%) with mNCCRCC among the entire cohort of 1,922 patients were analyzed. Both models were applied to predict first-line progression-free survival (PFS), total PFS, and cancer-specific survival (CSS). Results The median first-line PFS, total PFS, and CSS were 5, 6, and 24 months, respectively. The IMDC risk model reliably discriminated three risk groups to predict survival: the median firstline PFS, total PFS, and CSS for the favorable, intermediate, and poor risk groups were 9, 5, and, 2 months (p=0.001); 14, 7, and 2 months (p < 0.001); and 41, 21, and 8 months (p < 0.001), all respectively. The MSKCC risk model also reliably differentiated three risk groups: 9, 5, and, 2 months (p=0.005); 10, 7, and 3 months (p=0.002); and 50, 21, and 8 months (p < 0.001), also all respectively. The concordance indices were 0.632 with the IMDC model and 0.643 with the MSKCC model for first-line PFS: 0.748 and 0.655 for CSS. Conclusion The current IMDC and MSKCC risk models reliably predict first-line PFS, total PFS, and CSS in mNCCRCC.
참고문헌 (20)
- Siegel R, "Cancer statistics, 2012", CA Cancer J Clin, 62, pp.10~29 (2012)
- Lopez-Beltran A, "2004WHO classification of the renal tumors of the adults", Eur Urol, 49, pp.798~805 (2006)
- Motzer RJ, "NCCN clinical practice guidelines in oncology : kidney cancer", J Natl Compr Canc Netw, 7, pp.618~630 (2009)
- Oudard S, "Treatment options in renal cell carcinoma: past, present and future", Ann Oncol, 18(Suppl 10), pp.x25~x31 (2007)
- Patard JJ, "ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease", Eur Urol, 60, pp.684~690 (2011)
- Atkins MB, "Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer : a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial", Lancet Oncol, 19, pp.405~415 (2018)
- Powles T, "Updated European Association of Urology guidelines recommendations for the treatment of first-line metastatic clear cell renal cancer", Eur Urol, 73, pp.311~315 (2018)
- Heng DY, "Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents : results from a large, multicenter study", J Clin Oncol, 27, pp.5794~5799 (2009)
- Heng DY, "External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model : a population-based study", Lancet Oncol, 14, pp.141~148 (2013)
- Motzer RJ, "Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma", J Clin Oncol, 22, pp.454~463 (2004)
- Kroeger N, "Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents : characterization of survival outcome and application of the International mRCC Database Consortium criteria", Cancer, 119, pp.2999~3006 (2013)
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Pencina MJ, "Overall C as a measure of discrim-ination in survival analysis : model specific population value and confidence interval estimation", Stat Med, 23, pp.2109~2123 (2004)
- Fernandez-Pello S, "A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma", Eur Urol, 71, pp.426~436 (2017)
- Armstrong AJ, "Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma(ASPEN) : a multicentre, open-label, randomised phase 2 trial", Lancet Oncol, 17, pp.378~388 (2016)
- Cohen HT, "Renal-cell carcinoma", N Engl J Med, 353, pp.2477~2490 (2005)
- 정재영, "Current Trends in the Incidence and Survival Rate of Urological Cancers in Korea", Cancer Research and Treatment, 49(3), pp.607~615 (2017), 대한암학회
- Upton MP, "Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy", J Immunother, 28, pp.488~495 (2005)
- Ko JJ, "The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy : a population-based study", Lancet Oncol, 16, pp.293~300 (2015)
- Kwon WA, "Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib", Ann Surg Oncol, 20, pp.4397~4404 (2013)